| Cat.No. | Name | Information |
|---|---|---|
| M10139 | Anakinra | Anakinra (Raleukin) is an antagonist of recombinant, nonglycosylated human IL-1R. |
| M6223 | Tocilizumab | Tocilizumab is a humanized monoclonal antibody that binds to the interleukin-6 receptor. Tocilizumab prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab can be used for the research of rheumatoid arthritis and COVID-19. |
| M6189 | Ossirene | Ossirene (AS101), a potent in vitro and in vivo immunomodulator, is a novel inhibitor of IL-1beta (IL-1β) converting enzyme. Ossirene abolishes phosphorylation of STAT3 by inhibiting IL-10. Ossirene also inhibits Caspase-1. |
| M1622 | Secukinumab | Secukinumab (AIN457) is a high-affinity monoclonal antibody against interleukin (IL-17A). Secukinumab (AIN457) is the first-in-class anti-IL-17 agent to be used in studies of plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis. |
| M56365 | IL-17 modulator 4 | IL-17 modulator 4 is a proagent of IL-17 modulator 1. IL-17 modulator 1 is an orally active, highly efficacious IL-17 modulator. IL-17 modulator 4 is promising for the research of IL-17A mediated diseases, including inflammation, autoimmune diseases, infectious diseases, cancer, and precancerous syndrome. |
| M55699 | Taurohyodeoxycholic acid sodium | Taurohyodeoxycholic acid (THDCA) sodium prevents apoptosis by blocking a calcium-mediated apoptotic pathway as well as caspase-12 activation. Taurohyodeoxycholic acid sodium can also reduce the activity and expression of myeloperoxidase TNF-α and IL-6, as well as colonic damage in TNBS-induced ulcerative colitis mouse model. |
| M55336 | IL-4-inhibitor-1 | IL-4-inhibitor-1 is the first IL-4 small-molecule inhibitor, with an EC50 of 1.81 µM. IL-4-inhibitor-1 features a nicotinonitrile scaffold with micromolar affinity and potency for the cytokine and disrupts type II IL-4 signaling in cells. |
| M54800 | 13-Methylberberine chloride | 13-Methylberberine chloride is a berberine analogue, has anti-adipogenic and antitumor activities. 13-Methylberberine chloride increases production of IL-12 and inhibits the expression of iNOS at posttranscriptional level in macrophages activated with LPS. |
| M54551 | Rademikibart | Rademikibart is a human IgG4ҡ monoclonal antibody that targets IL-4 Rα to block inflammatory signaling induced by IL-4 and IL-13, two important cytokines that drive allergic inflammation, and binds to the human IL-4Rα epitope with a KD of 20.7 pM. Rademikibart does not bind to IL-4Rα from other species. Rademikibart does not bind to IL-4Rα of other species.Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation, and TARC production in PBMC, and can be used in studies related to moderate-to-severe Th2 inflammatory diseases. |
| M54371 | Erepdekinra | Erepdekinra is an interleukin-17A (IL-17A) receptor antagonist. |
| M53841 | Ac-YVAD-CHO | Ac-YVAD-CHO (L-709049) is a potent, reversible, specific tetrapeptide interleukin-lβ converting enzyme (ICE) inhibitor with mouse and human Ki values of 3.0 and 0.76 nM. |
| M49644 | Lysophosphatidylcholines | Lysophosphatidylcholines is an orally active lysolipid and a component of oxidized low density lipoprotein (LDL). |
| M40876 | Ebdarokimab | Ebdarokimab is a monoclonal antibody to IL-12p40/IL-23 that can be used in studies related to inflammatory bowel disease (IBD). |
| M40875 | Brazikumab | Brazikumab is a human IgG2 monoclonal antibody targeting IL-23 that selectively binds to the p19 subunit of IL-23 and has a KD value of 0.138 nM against human IL-23 for Crohn's disease (CD). |
| M40609 | Eblasakimab | Eblasakimab is a potential first-in-class, novel monoclonal antibody that targets the IL-13 receptor alpha 1 subunit (IL-13Rα1) and inhibits signaling of the pro-inflammatory cytokines IL-4 and IL-13. It can be used in studies related to atopic dermatitis (AD). |
| M30835 | Lipoxin A4 | Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways. Lipoxin A4 inhibits serum amyloid A (SAA)-mediated IL-8 release with an IC50 value of 25.74 nM. |
| M29648 | IL-17 modulator 1 disodium | IL-17 modulator 1 (disodium) is an orally active, highly efficacious IL-17 modulator. IL-17 modulator 1 (disodium) can be used for the research of diseases including psoriasis, ankylosing spondylitis and psoriatic arthritis. |
| M25387 | Daclizumab | Daclizumab (Zenapax) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (Zenapax) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA. |
| M25309 | Lebrikizumab | Lebrikizumab is a humanized monoclonal antibody to IgG4κ that binds with high affinity and specificity to interleukin 13 (IL-13) and inhibits its function, thereby preventing the formation of the IL-13Rα1/IL-4Rα complex and inhibiting the signaling pathway mediated by this receptor complex.Lebrikizumab has been used in asthma and atopic dermatitis studies. Lebrikizumab may be used in asthma and atopic dermatitis studies. |
| M25286 | Canakinumab | Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
